Daré Bioscience Inc (DARE)
NASDAQ:DARE
Want to see DARE full AI Analyst Report?
DARE Stock Chart & Stats
$1.70
-$0.06(-1.78%)
At close: 4:00 PM EST
$1.70
-$0.06(-1.78%)
Day’s Range― - ―
52-Week Range$1.27 - $9.19
Previous CloseN/A
Volume4.87K
Average Volume (3M)170.74K
Market Cap
$31.31M
Enterprise Value$2.90M
Total Cash (Recent Filing)$18.52M
Total Debt (Recent Filing)$1.61M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 06, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding14,979,502
10 Day Avg. Volume281,723
30 Day Avg. Volume170,743
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)75.90
Price to Sales (P/S)209.43
P/FCF Ratio-21.01
Enterprise Value/Market Cap0.09
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit44.99
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$10.00Price Target Upside488.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.95
Revenue Forecast (FY)$1.99M
Bulls Say, Bears Say
Bulls Say
Near-term Commercial RevenueAn imminent first product revenue event signals the company moving from development-only to commercialization. Durable impact: initial revenue can validate commercial execution, start product-level cash generation, support future payor/provider adoption, and materially reduce near-term dependence on financing if sustained.
Clinical And Regulatory ProgressConsecutive DSMB positivity and IND clearance materially de-risk development pathways across core programs. This strengthens regulatory credibility, enhances the probability of approvable endpoints, and preserves long-term optionality across multiple assets, supporting future approvals and commercial launches.
Significant Nondilutive Grant FundingLarge grant inflows materially extend runway and fund R&D without issuing equity. Structurally this lowers dilution risk, allows sustained program investment, and enables faster clinical progress relative to sole reliance on dilutive financings, improving strategic optionality and partnership leverage.
Bears Say
Negative Cash Flow And Operating LossesPersistent multi-million dollar negative operating and free cash flows indicate structural cash consumption that must be covered by financing or revenue. Over 2–6 months this limits flexibility, increases funding needs, and heightens the risk that R&D or commercialization investment must be curtailed if revenue timing slips.
Limited Near-term Liquidity/runwayLow working capital despite reported cash means operations rely on imminent revenue or additional financing. If product launch or dispensing timelines delay, the company may need dilutive capital raises or cutbacks, which could disrupt commercialization, slow trials, or weaken competitive positioning.
Balance-sheet Volatility And LeverageThin and volatile equity with elevated leverage constrains financial flexibility and increases likelihood of future dilution. Lenders and partners may demand stricter terms; volatile equity can complicate partnerships and support, weakening long-term strategic execution and making large investments costlier.
Daré Bioscience News
DARE FAQ
What was Daré Bioscience Inc’s price range in the past 12 months?
Daré Bioscience Inc lowest stock price was $1.27 and its highest was $9.19 in the past 12 months.
What is Daré Bioscience Inc’s market cap?
Daré Bioscience Inc’s market cap is $31.31M.
When is Daré Bioscience Inc’s upcoming earnings report date?
Daré Bioscience Inc’s upcoming earnings report date is Aug 06, 2026 which is in 39 days.
How were Daré Bioscience Inc’s earnings last quarter?
Daré Bioscience Inc released its earnings results on May 14, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.305 by $0.105.
Is Daré Bioscience Inc overvalued?
According to Wall Street analysts Daré Bioscience Inc’s price is currently Undervalued.
Does Daré Bioscience Inc pay dividends?
Daré Bioscience Inc does not currently pay dividends.
What is Daré Bioscience Inc’s EPS estimate?
Daré Bioscience Inc’s EPS estimate is -0.3.
How many shares outstanding does Daré Bioscience Inc have?
Daré Bioscience Inc has 14,979,502 shares outstanding.
What happened to Daré Bioscience Inc’s price movement after its last earnings report?
Daré Bioscience Inc reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.305. Following the earnings report the stock price went down -24.126%.
Which hedge fund is a major shareholder of Daré Bioscience Inc?
Currently, no hedge funds are holding shares in DARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Daré Bioscience Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (488.24% Upside)
$10.00 (488.24% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.61%
12-Months-Change
Fundamentals
Return on Equity
763.44%
Trailing 12-Months
Asset Growth
49.46%
Trailing 12-Months
Company Description
Daré Bioscience Inc
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
DARE Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call presents a constructive and catalytic picture: multiple near-term commercial milestones (Flora Sync LF5 launch in June, DARE to PLAY dispensing targeted this summer, first product revenue for the company) and positive clinical progress (Ovaprene DSMB review, DARE-HPV IND and Phase II start) are strong positives. These are balanced against material execution and financing risks — limited cash/working capital, need to raise capital absent revenue, state-by-state fulfillment delays and tolerability-related discontinuations in the Ovaprene trial. On net, the multiple commercial and clinical catalysts combined with significant nondilutive grant funding and clear go-to-market plans slightly outweigh the operational and liquidity headwinds.View all DARE earnings summariesDARE Stock 12 Month Forecast
Average Price Target
$10.00
▲(488.24% Upside)
Technical Analysis
Vyome Holdings
―
Lunai Bioworks
―
Passage Bio
―
Neurosense Therapeutics Ltd.
―
Boundless Bio Inc.
―
Ownership Overview
7.10%
Insiders
3.88% Mutual Funds
0.08% Other Institutional Investors
85.76% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---